DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer

Genes (Basel). 2022 Jul 7;13(7):1213. doi: 10.3390/genes13071213.

Abstract

Tumor heterogeneity presents challenges for personalized diagnosis and treatment of cancer. The identification method of cancer-specific biomarkers has important applications for the diagnosis and treatment of cancer types. In this study, we analyzed the pan-cancer DNA methylation data from TCGA and GEO, and proposed a computational method to quantify the degree of specificity based on the level of DNA methylation of G protein-coupled receptor-related genes (GPCRs-related genes) and to identify specific GPCRs DNA methylation biomarkers (GRSDMs) in pan-cancer. Then, a ridge regression-based method was used to discover potential drugs through predicting the drug sensitivities of cancer samples. Finally, we predicted and verified 8 GRSDMs in adrenocortical carcinoma (ACC), rectum adenocarcinoma (READ), uveal Melanoma (UVM), thyroid carcinoma (THCA), and predicted 4 GRSDMs (F2RL3, DGKB, GRK5, PIK3R6) which were sensitive to 12 potential drugs. Our research provided a novel approach for the personalized diagnosis of cancer and informed individualized treatment decisions.

Keywords: DNA methylation; G protein-coupled receptor; biomarker; drug sensitivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • DNA Methylation / genetics
  • Genetic Markers
  • Humans
  • Melanoma* / genetics
  • Receptors, G-Protein-Coupled / genetics
  • Thyroid Neoplasms* / genetics

Substances

  • Biomarkers, Tumor
  • Genetic Markers
  • Receptors, G-Protein-Coupled

Grants and funding

This research was funded by National Natural Science Foundation of China [U20A20376, 61972116, 62102120]; Applied Technology Research and Development Project of Heilongjiang [GA20C018]; Heilongjiang Postdoctoral Fund [LBH-Z20158].